Krebs Biochemicals and Industries Limited — Results, 04-02-2025: Integrated Filing- Financial

Krebs Biochemicals & Industries Limited has announced a board meeting where the financial results for the quarter and half-year ended December 31, 2024, were approved. The company reported a significant loss in revenue, amounting to ₹1,972.84 crore (cr) for the nine months period. Additionally, four new directors have been appointed as independent directors, enhancing the board's expertise. These appointments, pending shareholder approval, aim to strengthen governance and oversight. This move could improve investor sentiment by showcasing proactive management changes, though the ongoing financial losses present a potential risk.